You ran an experiment and found something interesting.
Cells with high levels of Protein X seem to respond much better to Drug A. You repeat the experiment. Same result. You test another cell line. Still there.
This could make a good paper.
But then someone asks:
"So, what's the invention?"
That question can be surprisingly difficult to answer.
Scientists are trained to think about what they have discovered: a biological relationship, a mechanism, an unexpected observation.
Patent drafting asks a slightly different question:
What have you actually made, developed or worked out that can be put into practice?
Let's use a fictional Protein X project to see the difference.
The experiment
Imagine your lab is studying Drug A, an existing cancer drug.
You treat a panel of tumour cell lines with Drug A and notice something unexpected:
Cell lines expressing high levels of Protein X are much more sensitive to Drug A than cell lines expressing low levels of Protein X.
You investigate further.
Knocking down Protein X makes the cells less sensitive to Drug A. Increasing Protein X expression makes them more sensitive.
Your data suggest that Protein X expression is associated with response to Drug A.
That is scientifically interesting.
But where is the invention?
Bio terms
- Cell line — A population of cells grown in the laboratory and used as an experimental model.
- Knocking down — Experimentally reducing the amount of a particular gene or protein to see what happens when there is less of it.
- Expression — The production of a gene's RNA or protein product. Here, "high Protein X expression" simply means that the cells produce relatively large amounts of Protein X.
Start with the discovery
At the most basic level, you have discovered a relationship:
High Protein X expression is linked to greater sensitivity to Drug A.
That relationship may not have been known before.
But simply discovering something about biology does not necessarily mean that the discovery itself is the most useful way to define the invention.
Ask the next question:
What can we do with this knowledge?
Now several possibilities appear.
Invention 1: Use Protein X to identify patients for Drug A
Suppose your results suggest that patients whose tumours express high levels of Protein X are more likely to respond to Drug A.
The practical idea might be:
- obtain a tumour sample from a patient;
- determine the level of Protein X; and
- identify the patient as suitable for treatment with Drug A based on that level.
Now we have moved beyond:
"Protein X correlates with Drug A response."
We are describing a practical use of that discovery.
Depending on the jurisdiction and how the application is drafted, this could potentially lead to claims directed towards a biomarker-based method, diagnostic approach or patient-selection method.
And immediately, more questions appear.
How do you measure Protein X?
Protein expression by immunohistochemistry?
mRNA by RT-qPCR?
A sequencing assay?
What counts as "high"?
Compared with healthy tissue? A reference population? A predefined threshold?
Those details are not merely experimental trivia. They may help define what the invention actually is.
Bio terms
- Biomarker — A measurable biological characteristic that can provide information about a biological state. Here, Protein X is being investigated as an indicator of whether a patient may respond to Drug A.
- Immunohistochemistry (IHC) — A laboratory technique that uses antibodies to detect particular proteins in a tissue sample.
- mRNA — Messenger RNA, an intermediate molecule produced when a gene is being expressed. Measuring mRNA can provide an indication of how active a gene is.
- RT-qPCR — A laboratory technique commonly used to measure the amount of a particular RNA in a sample.
- Sequencing assay — A test that reads DNA or RNA sequences and can be used to detect or measure particular genetic features.
Invention 2: Treat a particular group of patients with Drug A
Perhaps the real insight is not the test itself.
Perhaps it is the recognition that Drug A should be used in a particular patient population.
For example, the invention might concern the use of Drug A to treat patients whose tumours have high Protein X expression.
That sounds very similar to the biomarker idea, but from a patent perspective it can be quite different.
One focuses on identifying the patient.
The other focuses on using the drug in the identified patient population.
The exact form in which such an invention can be claimed also depends on the patent law of the jurisdiction concerned, particularly for methods of medical treatment.
In Singapore, methods of treatment or diagnosis practised on the body are generally not patentable (Patents Act s 16(2)), while a substance/composition for such use can still be (s 16(3)); other offices treat method claims differently.
Same experimental result.
Potentially different inventions.
Invention 3: A diagnostic kit
Maybe your lab goes further.
You develop antibodies against Protein X, establish an assay protocol and determine a clinically useful threshold for predicting response to Drug A.
Now there may be another invention:
a kit for determining whether a patient is likely to respond to Drug A.
The kit might contain particular antibodies, reagents, controls or other components required to perform the test.
Again, notice what happened.
The original scientific observation has not changed:
Protein X is associated with Drug A response.
But the work built around that observation has produced something more concrete.
Bio terms
- Antibody — A protein that can bind specifically to a particular biological target. In laboratory tests, antibodies are commonly used to detect whether a particular protein is present in a sample.
Invention 4: A new combination therapy
Then your postdoc notices something else.
Drug B increases Protein X expression.
So you try giving Drug B first to increase Protein X, then Drug A.
The combination produces a much stronger anti-tumour effect than either treatment alone.
Now you may have another potential invention: a combination treatment involving Drug A and Drug B.
And perhaps the important feature is not merely using the two drugs together.
Maybe the sequence matters.
Drug B must be administered first, followed by Drug A 24 hours later.
If simultaneous administration does not produce the same effect, that timing may be an important part of the invention.
Bio terms
- Anti-tumour effect — An effect that inhibits, damages or reduces the growth or survival of tumour cells.
One experiment can contain several inventions
This is where researchers sometimes get tripped up.
They ask:
"Is my result patentable?"
That may be the wrong question.
A better question is:
"What inventions arise from what we have discovered?"
From our fictional Protein X project, we already have several possibilities:
- using Protein X as a biomarker for response to Drug A;
- selecting patients for Drug A treatment based on Protein X;
- a Protein X diagnostic assay or kit;
- treating a Protein-X-defined patient population with Drug A; and
- a Drug A + Drug B combination therapy, potentially with a particular dosing sequence.
These are related, but they are not necessarily the same invention.
And they may not all ultimately be patentable.
Prior art may already disclose some of them. Some may be too broad compared with what the experiments actually support. Some may face subject-matter restrictions in particular jurisdictions.
That analysis comes later.
The first job is simply to identify what the invention might be.
Read your results like an inventor, not just a scientist
When scientists look at data, we naturally ask:
What does this tell us about the biology?
For patents, ask one more question:
What can we now do with this discovery?
A paper might describe how Protein X regulates sensitivity to Drug A.
The invention might instead be using Protein X to select patients for Drug A, developing an assay to predict response, or using Drug B to sensitise tumours to Drug A.
The scientific discovery and the invention are related, but they are not necessarily the same thing.
Talk to your technology transfer team before the story is finished
You do not need to arrive at the technology transfer office with perfectly drafted patent claims.
What is useful is to bring the experimental story:
We observed X. We think it means Y. We found that doing Z produces this effect. Here is the data.
From there, the researchers, technology transfer team and patent professionals can work out where the potentially protectable inventions are and whether the data support them.
And ideally, have that conversation before the paper, conference abstract, poster or thesis disclosure becomes public.
You also do not need to wait for a patent to be granted before publishing. Patent prosecution can take years.
The important point is usually to file first and secure a filing date before making the invention public. Once the appropriate patent application has been filed, publication of the research can generally proceed without destroying the novelty of what was already disclosed in that application.
That is why the patent conversation needs to happen early.
The takeaway
An interesting result is not necessarily the invention.
Discovery: Protein X is associated with response to Drug A.
Invention: What can you actually do with that discovery?
A useful test is simple:
"We discovered X. So now we can ___."
What goes in that blank may be your invention.
Disclaimer: This article is for general education about patents, research commercialisation, and how scientific results relate to candidate inventions. It uses a fictional Protein X / Drug A / Drug B scenario for illustration only. It is not legal advice. Patent rules vary by jurisdiction; speak to your technology-transfer office or a qualified IP professional before filing or publishing.